Grufity logoGrufity logo

Adaptive Biotechnologies Corp Stock Research

ADPT

8.40USD+0.18(+2.19%)Market Closed

Market Summary

USD8.40+0.18
Market Closed
2.19%

ADPT Alerts

ADPT Stock Price

ADPT RSI Chart

ADPT Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-6

Price/Sales (Trailing)

6.49

EV/EBITDA

-4.36

Price/Free Cashflow

-6

ADPT Price/Sales (Trailing)

ADPT Profitability

EBT Margin

-129.82%

Return on Equity

-43.13%

Return on Assets

-23.37%

Free Cashflow Yield

-16.66%

ADPT Fundamentals

ADPT Revenue

Revenue (TTM)

185.3M

Revenue Y/Y

45.53%

Revenue Q/Q

15.4%

ADPT Earnings

Earnings (TTM)

-200.2M

Earnings Y/Y

34.68%

Earnings Q/Q

11.38%

Price Action

52 Week Range

5.9615.19
(Low)(High)

Last 7 days

-7.5%

Last 30 days

-5.4%

Last 90 days

1.1%

Trailing 12 Months

-23.5%

ADPT Financial Health

Current Ratio

5.12

ADPT Investor Care

Shares Dilution (1Y)

1.21%

Diluted EPS (TTM)

-1.4

Peers (Alternatives to Adaptive BioTech)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.4B
6.8B
-13.31% 3.22%
32.19
5.89
8.37% 3.64%
35.5B
4.6B
5.65% -27.02%
-8.07
7.75
1.28% -677.95%
32.5B
3.9B
-7.42% 9.05%
37.3
8.3
5.43% 13.46%
11.5B
1.1B
-5.60% -27.97%
44.06
10.31
8.77% 24.82%
MID-CAP
9.7B
801.5M
-9.29% 0.51%
52.37
12.15
19.54% 44.95%
SMALL-CAP
2.0B
128.3M
-11.70% -1.09%
-6.37
15.61
-1.69% -73.40%
1.2B
185.3M
-5.41% -23.53%
-6
6.49
20.06% 3.42%
450.3M
105.5M
-12.44% -50.56%
-4.66
4.27
-4.55% -67.63%
405.5M
127.3M
-23.43% -69.17%
-2.54
3.19
-12.28% -38.43%
341.8M
27.8M
-23.57% -31.43%
-2.58
12.29
54.62% -83.06%
271.1M
138.6M
-29.13% -76.08%
-8.07
1.96
32.30% -57.86%
121.5M
72.0M
-9.68% -16.83%
-7.37
1.69
6.82% 39.11%
117.4M
113.3M
-15.92% -55.18%
-12.34
1.04
-4.68% -3204.17%
54.2M
54.1M
-0.24% -45.98%
502.17
1
21.80% -72.38%

Financials for Adaptive BioTech

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue10.3%185,308,000168,040,000159,677,000154,522,000154,344,000
  S&GA Expenses-3.0%95,603,00098,583,000102,019,000100,954,00095,465,000
  R&D Expenses-2.4%141,756,000145,233,000145,647,000146,410,000142,343,000
EBITDA1.2%-190,369,000-192,659,000---
EBITDA Margin4.4%-1.19-1.25---
Earnings Before Taxes--207,298,000----
EBT Margin3.2%-1.30-1.34---
Interest Expenses62.3%4,238,0002,612,000---
Net Income9.6%-200,191,000-221,496,000-232,118,000-236,070,000-207,279,000
Net Income Margin18.0%-1.08-1.32-1.45-1.48-
Free Cahsflow13.2%-200,294,000-230,804,000-241,026,000-247,917,000-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-3.1%857884807858923
  Current Assets-0.4%562564439419403
    Cash Equivalents-58.6%90.0021876.00115139
  Inventory-16.7%14.0017.0019.0021.0019.00
  Net PPE-3.7%83.0087.0087.0086.0085.00
  Goodwill0%119119119119119
Liabilities-1.0%393396288305319
  Current Liabilities5.5%110104111115114
Shareholder's Equity-4.9%464488518553604
  Retained Earnings-4.6%-919-878-833-781-718
  Additional Paid-In Capital1.1%1,3871,3731,3581,3401,324
Accumulated Depreciation-36.00----
Shares Outstanding0.1%143143143142141
Minority Interest-157.7%-0.07-0.030.000.000.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations11.5%-183-207-208-198-192
  Share Based Compensation4.6%55.0053.0051.0048.0043.00
Cashflow From Investing-98.3%3.0016888.00125181
Cashflow From Financing-2.4%13213613.0015.0027.00

Risks for ADPT

What is the probability of a big loss on ADPT?

98.5%


Probability that Adaptive BioTech stock will be more than 20% underwater in next one year

92.3%


Probability that Adaptive BioTech stock will be more than 30% underwater in next one year.

90.8%


Probability that Adaptive BioTech stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ADPT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Adaptive BioTech was unfortunately bought at previous high price.

Drawdowns

Returns for ADPT

Cumulative Returns on ADPT

-25.3%


3-Year Cumulative Returns

Which funds bought or sold ADPT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-0.04
8,407
121,407
-%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-5.96
11,000
1,271,000
0.01%
2023-03-03
TIAA, FSB
reduced
-14.83
-16,471
175,529
-%
2023-02-28
Voya Investment Management LLC
unchanged
-
22,444
329,444
-%
2023-02-22
CVA Family Office, LLC
unchanged
-
247
3,247
-%
2023-02-21
MACQUARIE GROUP LTD
reduced
-24.51
-111,000
442,000
-%
2023-02-16
HARBOUR INVESTMENTS, INC.
unchanged
-
-183
817
-%
2023-02-15
CAPTRUST FINANCIAL ADVISORS
sold off
-100
-88,000
-
-%
2023-02-15
Cerity Partners LLC
reduced
-0.2
80,144
1,209,140
0.01%
2023-02-15
LAZARD ASSET MANAGEMENT LLC
reduced
-46.28
-1,148,000
1,563,000
-%

1–10 of 43

Latest Funds Activity

Are funds buying ADPT calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own ADPT
No. of Funds

Adaptive BioTech News

Scenari Economici

Le 1001 azioni che si sono schiantate sul mercato azionario USA.

Scenari Economici,
5 months ago

24/7 Wall St.

Nasdaq

Schedule 13G FIlings of Adaptive BioTech

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
blackrock inc.
8.7%
12,374,197
SC 13G
Feb 09, 2023
vanguard group inc
8.25%
11,794,168
SC 13G/A
Sep 12, 2022
price t rowe associates inc /md/
2.9%
4,081,518
SC 13G/A
Feb 14, 2022
matrix capital management company, lp
8.20%
11,572,590
SC 13G/A
Feb 14, 2022
viking global investors lp
21.3%
29,993,708
SC 13G/A
Feb 10, 2022
price t rowe associates inc /md/
10.0%
14,240,614
SC 13G/A
Feb 10, 2022
price t rowe associates inc /md/
9.4%
13,286,713
SC 13G
Feb 09, 2022
vanguard group inc
7.82%
11,031,288
SC 13G/A
Feb 16, 2021
viking global investors lp
21.9%
29,993,708
SC 13G/A
Feb 16, 2021
matrix capital management company, lp
9.59%
13,115,090
SC 13G/A

ADPT Fair Value

Adaptive BioTech fair value in different scenarios

The table shows the Fair Value estimates for Adaptive BioTech for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

0.90

-89.29%

1.11

-86.79%

1.71

-79.64%

2.82

-66.43%

4.33

-48.45%
Current Inflation

0.89

-89.40%

1.07

-87.26%

1.60

-80.95%

2.56

-69.52%

3.85

-54.17%
Very High Inflation

0.87

-89.64%

1.03

-87.74%

1.47

-82.50%

2.25

-73.21%

3.30

-60.71%

Historical Adaptive BioTech Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Adaptive BioTech

View All Filings
Date Filed Form Type Document
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading

Latest Insider Trading transactions for ADPT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-07
Taylor Stacy L
sold
-115,128
8.6
-13,387
svp and general counsel
2023-03-07
ADAMS R MARK
sold
-147,533
8.6
-17,155
chief operating officer
2023-03-07
SOOD NITIN
sold
-84,391
8.6
-9,813
chief commercial officer, mrd
2023-03-06
Taylor Stacy L
sold
-47,057
8.57
-5,491
svp and general counsel
2023-03-06
Conroy Kevin T
acquired
-
-
14,775
-
2023-03-06
LO FRANCIS
sold
-58,413
8.57
-6,816
chief people officer
2023-03-06
ADAMS R MARK
acquired
-
-
88,652
chief operating officer
2023-03-06
ROBINS HARLAN S
acquired
-
-
354,610
chief scientific officer
2023-03-06
HERSHBERG ROBERT
acquired
-
-
14,775
-
2023-03-06
LO FRANCIS
acquired
-
-
85,697
chief people officer

1–10 of 50

Chad Robins
860
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

ADPT Income Statement

2022-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue   
Revenue$ 185,308$ 154,344$ 98,382
Operating expenses   
Cost of revenue57,90949,30122,530
Research and development141,756142,343116,072
Sales and marketing95,60395,46561,358
General and administrative88,52774,50249,536
Amortization of intangible assets1,6991,6991,703
Total operating expenses385,494363,310251,199
Loss from operations(200,186)(208,966)(152,817)
Interest and other income, net4,0561,6686,590
Interest expense(4,238)  
Net loss(200,368)(207,298)(146,227)
Add: Net loss attributable to noncontrolling interest17719 
Net loss attributable to Adaptive Biotechnologies Corporation$ (200,191)$ (207,279)$ (146,227)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic$ (1.40)$ (1.48)$ (1.11)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic142,515,917140,354,915131,216,468
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted$ (1.40)$ (1.48)$ (1.11)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted142,515,917140,354,915131,216,468

ADPT Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Current assets  
Cash and cash equivalents$ 90,030,000$ 139,065,000
Short-term marketable securities (amortized cost of $412,282 and $214,115, respectively)408,166,000213,996,000
Accounts receivable, net40,057,00017,409,000
Inventory14,453,00019,263,000
Prepaid expenses and other current assets9,440,00013,015,000
Total current assets562,146,000402,748,000
Long-term assets  
Property and equipment, net83,447,00085,262,000
Operating lease right-of-use assets80,763,00087,678,000
Long-term marketable securities (amortized cost of $218,163)217,145,000
Restricted cash2,398,0002,138,000
Intangible assets, net6,827,0008,526,000
Goodwill118,972,000118,972,000
Other assets2,064,000875,000
Total assets856,617,000923,344,000
Current liabilities  
Accounts payable8,084,0003,307,000
Accrued liabilities12,424,0009,343,000
Accrued compensation and benefits15,935,00015,642,000
Current portion of operating lease liabilities9,230,0005,055,000
Current deferred revenue64,115,00080,460,000
Total current liabilities109,788,000113,807,000
Long-term liabilities  
Operating lease liabilities, less current portion98,772,000106,685,000
Deferred revenue, less current portion58,599,00098,750,000
Revenue interest liability, net125,360,000 
Total liabilities392,519,000319,242,000
Commitments and contingencies (Note 12) 
Shareholders’ equity  
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2022 and 2021; no shares issued and outstanding at December 31, 2022 and 2021
Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2022 and 2021; 143,105,002 and 141,393,865 shares issued and outstanding at December 31, 2022 and 2021, respectively14,00014,000
Additional paid-in capital1,387,349,0001,324,006,000
Accumulated other comprehensive loss(4,116,000)(1,137,000)
Accumulated deficit(919,082,000)(718,891,000)
Total Adaptive Biotechnologies Corporation shareholders’ equity464,165,000603,992,000
Noncontrolling interest(67,000)110,000
Total shareholders’ equity464,098,000604,102,000
Total liabilities and shareholders’ equity$ 856,617,000$ 923,344,000